Skip to main content
OpenTrials
Completed

NCT Number: NCT01963585

Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children

Background:

Bronchial hyper responsiveness (BHR) assessed by methacholine challenge test (MCT) may aid in the diagnosis of asthma, while negative MCT can help to exclude the diagnosis. Laboratory measures that predict the results of MCT are expected to reduce the number of procedures. The possible capacity of High sensitive C-reactive protein (hs-CRP), a marker of systemic inflammation, to predict negative or positive MCT in children has not been evaluated.

Aim: to evaluate the capacity of hs-CRP to predict positive or negative MCT in school aged children and to compare it with markers of airway inflammation: Fractional exhaled Nitric Oxide (FeNO) and markers of allergic sensitization (IgE and peripheral blood eosinophils).

Design: Prospective study evaluating these parameters in patients with positive and negative MCT.

Participant selection: The study population included subjects (age range 6 to 18 years) referred for Methacholine Challenge Test (MCT)

Sample size: 130 participants in the two groups. Intervention: Each subject will undergo evaluation including a respiratory questionnaire, methacholine challenge test with determination of PC20(the provocative concentration that reduced FEV1 by 20% from baseline), exhaled nitric oxide (eNO). Venous blood will be analyzed for complete blood count + eosinophils, IGE levels, hs-CRP. All measurements will be evaluated in a single 3 hour visit, with no follow up study visits.

Primary end point: hs-CRP levels as add on tool to predict negative or positive MCT in children Secondary outcome parameters: All other parameters are the secondary end points.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age range 6 to 18 years
  • Patient referred for Methacholine Challenge Test (MCT)

Exclusion criteria

  • Base line FEV1(forced expiratory volume in the first second) < 65%
  • The presence of other systemic or lung disease
  • Anti-inflammatory drugs
  • Upper respiratory tract infection in the last month

Treatment and study plan

Primary outcomes

  1. HIgh sensitive C-reactive protein

    Time frame: participants will be followed for the duration of hospital visit, an average of 3 hours

    in peripheral Blood count

Secondary outcomes

  1. Metacholine Challenge Test

    Time frame: participants will be followed for the duration of hospital visit, an average of 3 hours

    As assessed by methacholine challenge test with determination of PC20.

  2. IgE

    Time frame: participants will be followed for the duration of hospital visit, an average of 3 hours

    in peripheral Blood count

  3. complete blood count

    Time frame: participants will be followed for the duration of hospital visit, an average of 3 hours

    in peripheral Blood count

  4. Fractional Exhaled NO

    Time frame: participants will be followed for the duration of hospital visit, an average of 3 hours

    determination of exhaled NO in Exhaled breath

  5. body mass index

    Time frame: participants will be followed for the duration of hospital visit, an average of 3 hours

Sponsors and collaborators

Lead sponsor

Rambam Health Care Campus

Other

Registry information

Important dates

Study start
2011
Primary completion
2012
Study completion
2013
First posted
Oct 16, 2013
Registry last updated
Oct 16, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.